補体阻害剤の世界市場レポート 2025年

補体阻害剤市場規模は、今後数年間で飛躍的な成長が見込まれます。2029年にはCAGR39.3％で617億4,000万米ドルに成長します。予測期間の成長は、自己免疫疾患および炎症性疾患の罹患率の上昇、生物製剤およびバイオシミラー市場の拡大、臨床試験数の増加、長時間作用型の補体阻害剤の開発、新興国市場のヘルスケアインフラの改善、標的療法の採用拡大、高齢者人口の増加、生物製剤治療への患者アクセスの強化などに起因すると考えられます。この期間に予想される主な動向には、創薬における人工知能の統合、高度なバイオマーカー同定技術、患者反応を予測するための機械学習、長時間作用型製剤、補体系解析のための次世代シーケンサー、ハイスループットスクリーニングプラットフォーム、補体阻害試験のための臓器オンチップモデル、補体阻害剤開発のための3Dバイオプリンティング、治療効果を評価するためのリアルタイムモニタリングツールなどがあります。

個別化医療への注目の高まりが、今後数年間の補体阻害剤市場の成長を促進すると予想されます。個別化医療には、治療結果を最適化し、治療を改善するために、遺伝的、環境的、ライフスタイル的要因に基づいて個々の患者に合わせた治療を行うことが含まれます。個別化医療の採用が増加している背景には、ゲノミクスの進歩、バイオマーカーに基づく診断の利用可能性の拡大、データ分析技術の向上、より的を絞った効果的な治療に対する需要の高まりなどがあります。補体阻害剤は、患者固有の疾患プロファイル、遺伝子構成、補体活性レベルに基づいて補体系の特定の構成要素を標的とすることで、個別化医療と連携します。例えば、2024年2月、米国の非営利団体である個別化医療連合（PMC）は、米国食品医薬品局（FDA）が2023年に26の新しい個別化医薬品を承認したと報告しました。その結果、個別化医療への注目の高まりが補体阻害剤市場の成長を後押ししています。

補体阻害剤市場の主要企業は、さまざまな自己免疫疾患や炎症性疾患における補体系を効果的に制御するモノクローナル抗体の開発をますます進めています。モノクローナル抗体は、がん、自己免疫疾患、感染症などの治療を助けるために、抗原を特異的に標的にして結合するように設計された実験室で設計されたタンパク質です。例えば、スイスの製薬会社F.ホフマン・ラ・ロシュ社は2024年8月、欧州委員会から、C5阻害剤による治療歴のある、または治療歴のない発作性夜間ヘモグロビン尿症（PNH）の成人および青年を対象にデザインされたモノクローナル抗体であるピアスキー（クロバリマブ）の承認を取得しました。ピアスキー（クロバリマブ）は補体タンパク質C5を標的としてその切断を阻害することにより、膜攻撃複合体（MAC）の形成を阻害し、終末補体を介した血管内溶血を抑制します。このメカニズムにより、ヘモグロビン値が改善し、輸血の必要性が減少し、疲労や貧血などの症状が緩和され、最終的に患者のQOLが向上します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界補体阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の補体阻害剤市場：成長率分析
• 世界の補体阻害剤市場の実績：規模と成長, 2019-2024
• 世界の補体阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界補体阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の補体阻害剤市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 補体成分3（C3）阻害剤
• 補体成分5（C5）阻害剤
• 補体因子D阻害剤
• 世界の補体阻害剤市場作用機序別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 代替経路阻害剤
• 古典的経路阻害剤
• レクチン経路阻害剤
• 世界の補体阻害剤市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非典型溶血性尿毒症症候群（aHUS）
• 全身性重症筋無力症（gMG）
• 発作性夜間血色素尿症（PNH）
• 世界の補体阻害剤市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内（IV）
• 皮下（SC）
• 世界の補体阻害剤市場患者の人口統計別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 成人用
• 高齢者
• 小児科
• 世界の補体阻害剤市場補体成分3（C3）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低分子C3阻害剤
• モノクローナル抗体C3阻害剤
• ペプチドベースのC3阻害剤
• 世界の補体阻害剤市場補体成分5（C5）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体C5阻害剤
• 低分子C5阻害剤
• RNAベースのC5阻害剤
• 世界の補体阻害剤市場補体因子D阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小分子因子D阻害剤
• モノクローナル抗体因子D阻害剤

第7章 地域別・国別分析

• 世界の補体阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の補体阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 補体阻害剤市場：競合情勢
• 補体阻害剤市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• CSL Behring
• UCB S.A.
• Takeda Pharmaceutical Company Limited
• Alnylam Pharmaceuticals Inc.
• Innovent Biologics Inc.
• BioCryst Pharmaceuticals Inc.
• Pharming Group N.V.
• Apellis Pharmaceuticals Inc.
• Omeros Corporation
• Akari Therapeutics Plc
• InflaRx N.V.
• Kira Pharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 補体阻害剤市場2029：新たな機会を提供する国
• 補体阻害剤市場2029：新たな機会を提供するセグメント
• 補体阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Complement inhibitors are therapeutic agents designed to regulate or block the complement system, a crucial part of the immune response involved in inflammation, pathogen elimination, and cell lysis. These inhibitors target specific complement components, such as complement component 3 (C3) or complement component 5 (C5), to prevent overactivation and reduce tissue damage in conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

The key product types in the complement inhibitors market include complement component 3 (C3) inhibitors, complement component 5 (C5) inhibitors, and complement factor D inhibitors. C3 inhibitors are therapeutic agents that block the activation of C3, a central protein in the complement cascade. The mechanisms of action for complement inhibitors involve alternative pathway inhibitors, classical pathway inhibitors, and lectin pathway inhibitors. These therapies are used to treat conditions such as aHUS, generalized myasthenia gravis (GMG), and PNH. Administration routes include intravenous (IV) and subcutaneous (SC) methods, serving a broad patient demographic, including adults, geriatrics, and pediatrics.

The complement inhibitors market research report is one of a series of new reports from The Business Research Company that provides complement inhibitors market statistics, including complement inhibitors industry global market size, regional shares, competitors with a complement inhibitors market share, detailed complement inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the complement inhibitors industry. This complement inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The complement inhibitors market size has grown exponentially in recent years. It will grow from $16.41 billion in 2024 to $21.43 billion in 2025 at a compound annual growth rate (CAGR) of 30.6%. The growth during the historic period can be attributed to the increasing prevalence of complement-mediated diseases, rising awareness of rare diseases, the emergence of biologics as effective therapies, growing healthcare expenditure, a stronger focus on personalized medicine, the availability of orphan drug incentives, regulatory support for rare disease treatments, and enhanced collaborations between pharmaceutical companies and research institutions.

The complement inhibitors market size is expected to see exponential growth in the next few years. It will grow to $61.74 billion in 2029 at a compound annual growth rate (CAGR) of 39.3%. The growth in the forecast period can be attributed to the rising incidence of autoimmune and inflammatory diseases, expansion of the biologics and biosimilars markets, an increasing number of clinical trials, the development of longer-acting complement inhibitors, improved healthcare infrastructure in emerging markets, greater adoption of targeted therapies, a growing geriatric population, and enhanced patient access to biologic treatments. Key trends expected during this period include the integration of artificial intelligence in drug discovery, advanced biomarker identification techniques, machine learning for predicting patient responses, long-acting drug formulations, next-generation sequencing for complement system analysis, high-throughput screening platforms, organ-on-a-chip models for complement inhibition testing, 3D bioprinting for complement inhibitor development, and real-time monitoring tools for assessing treatment efficacy.

The increasing focus on personalized medicine is expected to drive the growth of the complement inhibitors market in the coming years. Personalized medicine involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The rising adoption of personalized medicine is fueled by advancements in genomics, the growing availability of biomarker-based diagnostics, improved data analytics technologies, and a growing demand for more targeted and effective therapies. Complement inhibitors align with personalized medicine by targeting specific components of the complement system based on a patient's unique disease profile, genetic makeup, and complement activity levels. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable increase from 12 approvals in 2022. As a result, the expanding focus on personalized medicine is fueling the growth of the complement inhibitors market.

Leading companies in the complement inhibitors market are increasingly developing monoclonal antibodies to effectively regulate the complement system in various autoimmune and inflammatory diseases. Monoclonal antibodies are lab-engineered proteins designed to specifically target and bind to antigens, aiding in the treatment of conditions such as cancer, autoimmune disorders, and infections. For example, in August 2024, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, received approval from the European Commission for PiaSky (crovalimab), a monoclonal antibody designed for adults and adolescents with paroxysmal nocturnal hemoglobinuria (PNH) who are either new to or previously treated with C5 inhibitors. PiaSky (crovalimab) targets complement protein C5 to prevent its cleavage, thereby inhibiting the formation of the membrane attack complex (MAC) and reducing terminal complement-mediated intravascular hemolysis. This mechanism helps improve hemoglobin levels, decrease the need for blood transfusions, and alleviate symptoms such as fatigue and anemia, ultimately enhancing patients' quality of life.

In September 2023, Magenta Therapeutics Inc., a US-based clinical-stage biotechnology company, merged with Dianthus Therapeutics Inc. for an undisclosed amount. This merger enables the combined company to focus on advancing Dianthus' pipeline of next-generation complement inhibitors, including DNTH103, which is currently in a Phase I clinical trial. Dianthus Therapeutics Inc. is a US-based clinical-stage biotechnology company specializing in developing next-generation antibody complement therapeutics for severe autoimmune diseases.

Major players in the complement inhibitors market are F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Behring, UCB S.A., Takeda Pharmaceutical Company Limited, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., BioCryst Pharmaceuticals Inc., Pharming Group N.V., Apellis Pharmaceuticals Inc., Omeros Corporation, Akari Therapeutics Plc, InflaRx N.V., Kira Pharmaceuticals.

North America was the largest region in the complement inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in complement inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the complement inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The complement inhibitors market consists of sales of small molecule inhibitors, recombinant proteins and biologics designed to regulate the complement system and treat complement-mediated diseases. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Complement Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on complement inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for complement inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The complement inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Complement Component 3 (C3) Inhibitors; Complement Component 5 (C5) Inhibitors; Complement Factor D Inhibitors
• 2) By Mechanism Of Action: Alternative Pathway Inhibitors; Classic Pathway Inhibitors; Lectin Pathway Inhibitors
• 3) By Indication: Atypical Hemolytic Uremic Syndrome (aHUS); Generalized Myasthenia Gravis (gMG); Paroxysmal Nocturnal Hemoglobinuria (PNH)
• 4) By Route Of Administration: Intravenous (IV); Subcutaneous (SC)
• 5) By Patient Demographics: Adult; Geriatric; Pediatric
• Subsegments:
• 1) By Complement Component 3 (C3) Inhibitors: Small Molecule C3 Inhibitors; Monoclonal Antibody C3 Inhibitors; Peptide-Based C3 Inhibitors
• 2) By Complement Component 5 (C5) Inhibitors: Monoclonal Antibody C5 Inhibitors; Small Molecule C5 Inhibitors; RNA-Based C5 Inhibitors
• 3) By Complement Factor D Inhibitors: Small Molecule Factor D Inhibitors; Monoclonal Antibody Factor D Inhibitors
• Companies Mentioned: F. Hoffmann-La Roche AG; Bayer AG; Sanofi S.A.; AstraZeneca plc; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Complement Inhibitors Market Characteristics

3. Complement Inhibitors Market Trends And Strategies

4. Complement Inhibitors Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Complement Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Complement Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Complement Inhibitors Market Growth Rate Analysis
• 5.4. Global Complement Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Complement Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Complement Inhibitors Total Addressable Market (TAM)

6. Complement Inhibitors Market Segmentation

• 6.1. Global Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Complement Component 3 (C3) Inhibitors
• Complement Component 5 (C5) Inhibitors
• Complement Factor D Inhibitors
• 6.2. Global Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alternative Pathway Inhibitors
• Classic Pathway Inhibitors
• Lectin Pathway Inhibitors
• 6.3. Global Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atypical Hemolytic Uremic Syndrome (aHUS)
• Generalized Myasthenia Gravis (gMG)
• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• 6.4. Global Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV)
• Subcutaneous (SC)
• 6.5. Global Complement Inhibitors Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult
• Geriatric
• Pediatric
• 6.6. Global Complement Inhibitors Market, Sub-Segmentation Of Complement Component 3 (C3) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Molecule C3 Inhibitors
• Monoclonal Antibody C3 Inhibitors
• Peptide-Based C3 Inhibitors
• 6.7. Global Complement Inhibitors Market, Sub-Segmentation Of Complement Component 5 (C5) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibody C5 Inhibitors
• Small Molecule C5 Inhibitors
• RNA-Based C5 Inhibitors
• 6.8. Global Complement Inhibitors Market, Sub-Segmentation Of Complement Factor D Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Molecule Factor D Inhibitors
• Monoclonal Antibody Factor D Inhibitors

7. Complement Inhibitors Market Regional And Country Analysis

• 7.1. Global Complement Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Complement Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Complement Inhibitors Market

• 8.1. Asia-Pacific Complement Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Complement Inhibitors Market

• 9.1. China Complement Inhibitors Market Overview
• 9.2. China Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Complement Inhibitors Market

• 10.1. India Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Complement Inhibitors Market

• 11.1. Japan Complement Inhibitors Market Overview
• 11.2. Japan Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Complement Inhibitors Market

• 12.1. Australia Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Complement Inhibitors Market

• 13.1. Indonesia Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Complement Inhibitors Market

• 14.1. South Korea Complement Inhibitors Market Overview
• 14.2. South Korea Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Complement Inhibitors Market

• 15.1. Western Europe Complement Inhibitors Market Overview
• 15.2. Western Europe Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Complement Inhibitors Market

• 16.1. UK Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Complement Inhibitors Market

• 17.1. Germany Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Complement Inhibitors Market

• 18.1. France Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Complement Inhibitors Market

• 19.1. Italy Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Complement Inhibitors Market

• 20.1. Spain Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Complement Inhibitors Market

• 21.1. Eastern Europe Complement Inhibitors Market Overview
• 21.2. Eastern Europe Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Complement Inhibitors Market

• 22.1. Russia Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Complement Inhibitors Market

• 23.1. North America Complement Inhibitors Market Overview
• 23.2. North America Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Complement Inhibitors Market

• 24.1. USA Complement Inhibitors Market Overview
• 24.2. USA Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Complement Inhibitors Market

• 25.1. Canada Complement Inhibitors Market Overview
• 25.2. Canada Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Complement Inhibitors Market

• 26.1. South America Complement Inhibitors Market Overview
• 26.2. South America Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Complement Inhibitors Market

• 27.1. Brazil Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Complement Inhibitors Market

• 28.1. Middle East Complement Inhibitors Market Overview
• 28.2. Middle East Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Complement Inhibitors Market

• 29.1. Africa Complement Inhibitors Market Overview
• 29.2. Africa Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Complement Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Complement Inhibitors Market Competitive Landscape
• 30.2. Complement Inhibitors Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Complement Inhibitors Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Regeneron Pharmaceuticals Inc.
• 31.3. Astellas Pharma Inc.
• 31.4. CSL Behring
• 31.5. UCB S.A.
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Alnylam Pharmaceuticals Inc.
• 31.8. Innovent Biologics Inc.
• 31.9. BioCryst Pharmaceuticals Inc.
• 31.10. Pharming Group N.V.
• 31.11. Apellis Pharmaceuticals Inc.
• 31.12. Omeros Corporation
• 31.13. Akari Therapeutics Plc
• 31.14. InflaRx N.V.
• 31.15. Kira Pharmaceuticals

32. Global Complement Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Complement Inhibitors Market

34. Recent Developments In The Complement Inhibitors Market

35. Complement Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Complement Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Complement Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Complement Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer